Q3 2024 Evogene Ltd Earnings Call Transcript
Key Points
- Evogene Ltd (EVGN) reported a revenue increase to approximately $6.9 million for the first nine months of 2024, up from $5.1 million in the same period of 2023.
- The company completed a successful fundraising round in August 2024, raising $5.5 million in gross proceeds.
- Evogene Ltd (EVGN) announced a collaboration with Google Cloud to develop a generative AI foundation model for novel small molecule design, enhancing its ChemPass AI tech engine.
- Casterra, a subsidiary of Evogene Ltd (EVGN), achieved significant milestones in seed production infrastructure in Kenya and Brazil, supporting future seed demands.
- Lavie Bio, another subsidiary, expanded its product Yalos to new crops and markets, with initial sales expected to begin in spring 2025 for soybeans.
- Evogene Ltd (EVGN) experienced a decrease in Q3 2024 revenues to approximately $1.8 million from $3.8 million in Q3 2023, primarily due to a $2.5 million license fee received in the previous year.
- The company reported an operating loss of approximately $17.6 million for the first nine months of 2024, slightly down from $18.9 million in the same period of 2023.
- General and administrative expenses increased significantly to approximately $6.1 million for the first nine months of 2024, up from $4.8 million in the same period of the previous year.
- Evogene Ltd (EVGN) faced delays in seed deliveries due to extended rain seasons in Kenya, impacting Casterra's operations.
- The company reported a net loss of approximately $18 million for the first nine months of 2024, compared to $18.6 million in the same period of 2023, with increased financial expenses related to warrants issued in August 2024.
Welcome to Evogene's third quarter results conference call. (Operator Instructions) As a reminder, this conference is being recorded November 21, 2024.
This presentation contains forward-looking statements relating to future events and Evogene LTD may, from time to time, make other statements regarding our outlook or expectations of future financial or operating results and/or other matters regarding or affecting us that are considered forward-looking statements as defined in the US Private Securities Litigation Reform Act of 1995 and other securities laws as amended.
Statements that are not statements of historical fact may be deemed to be forward-looking statements. Such forward-looking statements may be identified by the use of such words as believe, expect, anticipate, should planned, estimated, intend and potential or words of similar meaning.
We are using forward-looking statements in this presentation when we discuss Evogene's strategy and vision, Evogene's value proposition and ability to identify and optimize candidates enhance the likelihood of achieving breakthrough
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
